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Introduction: Even if proprotein convertase subtilisin/kexin type 9 inhibitors have replaced 
lipoprotein apheresis in many patients, lipoprotein apheresis still is an important option in 
homozygous familial hypercholesterolemia, progressive atherosclerosis or when removal of 
lipoprotein(a) is indicated. Additional possible favorable effects beyond lipid lowering could 
include changes in the concentration of cytokines and improvement of hemorheology. 
Methods: We evaluated how whole blood adsorption, dextran sulfate plasma adsorption and 
double filtration plasmapheresis lipoprotein apheresis systems affected cytokine 
concentrations, using a human whole blood ex vivo model differentiating the effect of the 
lipoprotein apheresis and plasma separation columns and describing temporal changes. 
Results: Compared to the control bag, the whole blood adsorption system reduced IFN-γ, IL-
8, IL-1ra, eotaxin, TNF, MCP-1, PDGF-BB, RANTES, MIP-1β and IP-10 (p<0.05). The 
dextran sulfate plasma adsorption system reduced IFN-γ, IL-8, IL-1ra, eotaxin, TNF, MCP-1, 
PDGF-BB, MIP-1β and IP10 (p<0.05). VEGF and GM-CSF were increased in the whole 
blood and dextran sulfate plasma adsorption systems (p <0.05). The double filtration 
plasmapheresis system reduced IFN-γ, IL-1ra, TNF, MIP-1β and IP-10 (p<0.05), while MCP-
1,VEGF, GM-CSF and RANTES were increased (p <0.05). The plasma separation column 
increased concentration of RANTES, and was a barrier to reduction of eotaxin. Temporal 
patterns of concentration change indicated first pass increase of PDGF-BB and first pass 
reduction of IP-10. Conclusion: There were marked differences in how the three systems 
affected total and temporal cytokine concentration changes in this in vitro model, as well as 
compared to former in vivo studies.  
 




1. Introduction  
Lipoprotein apheresis has traditionally been used in cardiovascular risk reduction, when lipid 
lowering therapy was not tolerated or the therapeutic target was not achieved, in particular in 
patients with familial hypercholesterolemia 1-3. Beneficial effect on clinical endpoints was 
documented in the LAARS and L-CAPS study 4,5. As new types of lipid lowering therapy 
have emerged, in particular proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, 
the use of lipoprotein apheresis has diminished. However, it is still an option in homozygous 
familial hypercholesterolemia and for other selected high risk patients when pharmacological 
lipid lowering therapy fails to reduce low-density lipoprotein (LDL) cholesterol sufficiently. 
It can furthermore be a treatment option when progression of atherosclerosis is not inhibited, 
or when the concentration of lipoprotein (a) is high 2,6, since lipoprotein apheresis supersedes 
PCSK9 inhibition in reducing levels of lipoprotein (a) 7. Lipoprotein apheresis can be 
performed with columns designed for perfusion of whole blood or plasma and LDL 
cholesterol removal from plasma depends on plasma separation prior to LDL cholesterol 
removal. The mechanisms involved in lipoprotein apheresis are either adsorption or capture 
through filtration or precipitation 8. 
  
Promising results have been reported when using lipoprotein apheresis for other purposes than 
LDL cholesterol reduction. The American Society for Apheresis has published a guideline 
document indicating that lipoprotein apheresis could be of use in focal segmental 
glomerulosclerosis, sudden sensorineural hearing loss and phytanic acid storage disease 9. 
Lipoprotein apheresis has also shown promising results in treatment of nephropathy in 
diabetes mellitus 10,11 and nephrotic syndrome of various etiologies 12-14. It has been suggested 
that lipoprotein apheresis can reduce the risk of in-stent coronary restenosis in the early post-




due to below-knee arterial lesions 16,17. In these studies double filtration plasmapheresis, 
dextran sulfate plasma adsorption and heparin-induced, extracorporeal LDL precipitation 
were used as lipoprotein apheresis systems. Possible mechanisms for the effects include 
improvement of hemorheology, possibly trough cholesterol and/ -or fibrinogen removal, 
reduction of proinflammatory cytokines, adhesion molecules and lipoprotein (a), and the 
possible removal of a putative, yet still unknown, soluble factor in nephrotic syndrome. It has 
also been suggested that the reduction in LDL cholesterol itself reduces foam cell formation, 
modifying endothelial damage and inflammatory mechanisms with subsequent favorable 
clinical effects 15,18-20.  
It is well known from a biocompatibility perspective that lipoprotein apheresis and plasma 
separation columns modify the complement system and induce changes in the levels of 
cytokines 21. Furthermore, activation of immune cells and platelets occurs in lipoprotein 
apheresis, as in all forms of contact between blood and artificial surfaces 8,22. Our group has 
previously shown that different types of lipoprotein apheresis systems have different impact 
on the cytokine concentration and the complement system in vivo 23,24. Others have also 
studied changes of cytokines during lipoprotein apheresis, but the results are not entirely 
consistent 25. 
 
The aim of the present study was to investigate how different lipoprotein apheresis columns 
affect cytokines, including chemokines and growth factors. We used an ex vivo model with 
three commercially available lipoprotein apheresis systems. The model allowed for 
differentiation of effects between the plasma separation and the lipoprotein apheresis column, 






2. Methods  
Ethics 
The local ethics committee approved the study and all blood donors signed an informed 
consent. Blood was drawn from six healthy donors (three males and three females). Each 
individual donated 450 ml of blood three times at approximately one month intervals. 
 
Lipoprotein apheresis (Figure 1) 
The experimental setup has, beyond below stated, previously been described in detail 24. A 
short summary is given here. The blood pack used as both the sample control bag (SC) and 
the apheresis blood reservoir was made from polyvinylchloride copolymer plasticized with di-
2-ethylhexyl phthalate. Lepirudin (Refludan, Celgene, Marburg, Germany) was used as sole 
anticoagulant in all tree lipoprotein apheresis systems and in the SC bag, in this study. Blood 
flow in the whole blood adsorption lipoprotein apheresis system (DL75) (Filter DL75, Kaneka 
Corp., Osaka, Japan) was 30 ml/min. In the dextran sulfate plasma adsorption (LA15) (Filter 
LA15, Kaneka Corp., Osaka, Japan) and double filtration plasmapheresis (EC50) (Filter 
EC50, Asahi Kasei Medical, Europe) lipoprotein apheresis systems blood flow was 100 
ml/min and the plasma flow 20 ml/min. Six treatments were performed with each lipoprotein 
apheresis system. The same plasma separation column (PlasmaFlo OP05, Asahi Kasei 
Medical, Europe) was used in the two plasma separation lipoprotein apheresis systems. The 
three experimental apheresis models are illustrated in Figure 1, showing the whole blood 
adsorption lipoprotein apheresis system DL75 (A) and the dextran sulfate plasma adsorption 






Plasma samples were analyzed using a multiplex cytokine assay (Bio-Plex Pro Human 
Cytokine Grp I Panel 27-Plex; Bio-Rad Laboratories Inc., Hercules, CA) containing the 
following 27 analytes: Interleukin (IL)-1β (IL-1β), IL-1 receptor antagonist (IL-1ra), IL-2, IL-
4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-9, IL-10, IL- 12, IL-13, IL-15, IL-17, eotaxin (CCL11), 
basic fibroblast growth factor (FGF), granulocyte colony stimulating factor (G-CSF), 
granulocyte macrophage colony stimulating factor (GM-CSF), Interferon-γ (IFN-γ), 
chemokine (C-X-C motif) ligand 10 (IP-10 or CXCL10), monocyte chemoattractant protein 1 
(MCP-1 or CCL2), macrophage inflammatory protein (MIP) -1α (MIP-1α or CCL3), MIP-1β 
(or CCL4), platelet derived growth factor (PDGF), regulated on activation T cell expressed 
and secreted (RANTES or CCL5), tumor necrosis factor (TNF) and vascular endothelial 
growth factor (VEGF). The analysis was performed according to the manufacturer’s 
instructions. 
 
Calculations and statistics 
Results are presented as mean and SEM.  Statistical calculations presented were performed 
with Prism 7.05 for Windows, Graphpad software (San Diego, CA). For calculation of 
differences in SC between baseline (T0) and after 240 minutes perfusion (T240) a two-tailed 
unpaired students t-test was used. Significance level was set at <0.05. For pairwise 
comparison of the lipoprotein apheresis systems a regular two-way ANCOVA model with 








Overall concentration changes in the sample control bag and the lipoprotein apheresis 
systems (Fig. 2) 
The rationale for selecting the 27 cytokines was both to be able to compare results with 
formerly published data from our and other groups, and because these cytokines are included 
in a reliable test kit. Thirteen of the 27 cytokines analyzed in the multiplex cytokine assay 
gave qualitatively acceptable readouts within the limits of the assay used. The other cytokines 
were out of range and not usable for analysis. The results are presented in Table 1 and in 
Figure 2. Figure 2 is divided into A and B to discriminate between small (A) and large (B) 
concentration changes.  
 
Sample control bag 
In SC, IFN-γ, IL-8, IL-1ra, TNF, PDGF-BB, RANTES and MIP-1β increased in 
concentration at 240 minutes (T240) compared to baseline (T0) (p < 0.05) (Fig. 2A and B 
white bars). The other biomarkers did not differ in concentration in SC at T240 compared to 
baseline. 
 
DL75 lipoprotein apheresis system 
In the DL75 system IFN-γ, IL-8, IL-1ra, eotaxin, TNF, MCP-1, PDGF-BB, RANTES, MIP-
1β and IP-10 were reduced (p < 0.05), IL-17 was unchanged and VEGF and GM-CSF were 
increased (p < 0.05) in position blood sample 2 (BS2), before the apheresis blood reservoir, 
compared to the SC at T240. (Fig. 2A and B black bars). RANTES was reduced only in the 
DL75 lipoprotein apheresis system. The other parameters did not differ between the DL75 
and LA15 systems at T240. IL-8, eotaxin, MCP-1, PDGF-BB, RANTES, MIP-1β and IP-10 




0.05). The other biomarkers did not differ between the DL75 and EC50 systems at T240 
(Table 1).  
 
LA15 lipoprotein apheresis system 
In the LA15 system IFN-γ, IL-8, IL-1ra, eotaxin, TNF, MCP-1, PDGF-BB, MIP-1β and IP10 
were reduced (p <0.05), IL17 and RANTES was unchanged and VEGF and GM-CSF were 
increased (p <0.05) in position BS2 compared to the SC at T240. (Fig. 2A and B light grey 
bars). IL-8, eotaxin, MCP-1, PDGF-BB, RANTES, MIP-1β and IP-10 were reduced in the 
LA15 system compared to the EC50 system (p < 0.05). The other biomarkers did not differ 
between the LA15 and EC50 systems at T240 (Table 1). 
 
EC50 lipoprotein apheresis system 
In the EC50 system IFN-γ, IL-1ra, TNF, MIP-1β and IP-10 were reduced (p<0.05), IL-8, 
eotaxin, IL17 and PDGF-BB were unchanged and MCP-1,VEGF, GM-CSF and RANTES 
were increased (p <0.05) in position BS2 compared to the SC at T240 (Fig. 2A and B dark 




Temporal patterns of concentration change  
The biomarkers eotaxin, RANTES, PDGF-BB and IP-10 were chosen to describe temporal 
patterns of concentration change in lipoprotein apheresis systems. Detailed figures of the 






Eotaxin (Fig. 3) 
Eotaxin concentration was unchanged from baseline to T240 in SC (Fig. 3A, B, C).  
In the DL75 system, position BS2, eotaxin showed a marked reduction from T0 to T15 and 
remained on this level until T240.  (Fig. 3A and F). In the LA15 system, plasma sample 1 
(PS1), position post plasma separation, concentration of eotaxin was reduced from 158.3 
pg/ml ± 44.8 at T0 to 46.2 pg/ml ± 14.9 at T15 (Fig. 3B, D). The concentration remained on 
this level until T240, indicating only minor filtration of eotaxin into plasma in the plasma 
separation column. In position BS2 eotaxin concentration was reduced gradually from 158.3 
pg/ml ± 44.9 at T0 to 55.1 pg/ml ± 20.2 at T240 indicating reduction in the LA15 column (Fig 
3B, F). In the EC50 system, position PS1, a similar pattern was seen as for the LA15 system 
(Fig 3C, D), however in position PS2, eotaxin increased slightly from T15 until T240 (Fig. 
3C, E).  
 
PDGF-BB (Fig. 4)  
PDGF-BB concentration increased 25-fold from baseline to T240 in SC (Fig. 5A, B, C). In 
the DL75 system, position blood sample 1 (BS1), after the blood reservoir, PDGF-BB 
increased from 42.4 pg/ml ± 8.9 at T0 to 1563.7 pg/ml ± 246.4 at T15. From T15 PDGF-BB 
was reduced to 276.5 pg/ml ± 70.9 at T30 (Fig. 5A), indicating a pattern of first pass increase 
and reduction of concentration.  In the LA15 system, position PS1, there was a 30-fold 
increase in concentration from T0 to T120 (Fig. 5A, D). From T120 until T240 there was a 
decrease in concentration towards baseline (Fig 5B, F). In position PS2 the concentration 
stayed at baseline from T0 to T240 (Fig 5B, E) indicating effective reduction in the LA15 
column. In the EC50 system, positions BS1, BS2, PS1 and PS2, there was a 40-fold gradual 





RANTES (Fig. 5) 
RANTES concentration increased from baseline to T240 in SC (Fig. 5A, B, C). In the DL75 
system, position BS1, RANTES increased 4-fold until T15 before a gradual reduction to 
below baseline at T240 (Fig 5A). In the LA15 system, position BS2, concentration increased 
form baseline to T240 (Fig 5B, F) indicating that the LA15 system as a whole increased the 
concentration of RANTES. In position PS1 the same pattern was seen as in position BS2 (Fig. 
5B, E), however in position PS2 there was a reduction from 748.8 pg/ml ± 342.5 at T0 to 8.1 
pg/ml ± 1.0 at T15 (Fig 5B,E). The concentration was at this level until T240 indicating 
effective reduction of RANTES in the LA15 column. In the EC50 system, position BS1, BS2, 
PS1 and PS2, there was an increase in concentration of RANTES from T0 until T240 (Fig 5C, 
D, E, F) 
 
IP-10 (Fig. 6) 
IP-10 concentration was unchanged from baseline to T240 in SC (Fig. 6A, B, C). In the DL75 
system, position BS2, the IP-10 concentration was markedly reduced from T0 to T15 (Fig. 
6A, F), and remained on a low level until T240. In the LA15 system, position PS1, there was 
a gradual fall in concentration from T0 to T240 (Fig 6B, D). In position PS2 there was an 
initial fall from 1048.5 pg/ml ± 230.1 at T0 to 39.1 pg/ml ± 0.9 at T15 and then continuously 
low concentration until T240. In the position BS2 there also was a gradual concentration 
reduction from T0 until T240 (Fig 6B, F). This indicates effective reduction of IP-10 in the 
DL75 and LA15 columns (Fig 6B, E). In the EC50 column, position PS1, there was a fall 
from T0 to T15 after which the concentration remained stable until T240 (Fig 6C, D). In 
position PS2 there was a reduction from 1284.6 pg/ml ± 224.9 at T0 to 104.0 pg/ml ± 24.5 at 
T15, before an increase in concentration to 582.4 pg/ml ± 98.0 at T30, indicating a first pass 




6C, E).  In position BS2 there was an initial reduction from T0 to T15 and thereafter a stable 





4. Discussion  
Several studies presenting changes in inflammatory biomarkers, hemorheological parameters 
and oxidative stress during in vivo lipoprotein apheresis with different columns have been 
published 21,23,26-28. To our knowledge, this is the first study presenting a systematic 
comparison of three lipoprotein apheresis systems’ impact on cytokines, also including 
temporal changes, in an ex vivo model.  Fourteen of the 27 cytokines were out of range in the 
laboratory test kit used in this study and not usable for further analysis. It is known that the 
hemorheology is influenced by the level of cholesterol29 and this might impact on the 
inflammation responses and the results from the test kit used in this study as the blood donors 
were healthy volunteers.  
 
Uniform concentration changes in the SC indicate robust and stable testing conditions. The 
rate of increase in cytokine concentrations in SC were slow compared to changes in the 
apheresis systems as seen for RANTES and PDGF. Other biomarkers as VEGF, GM-CSF and 
IP-10 showed only a small or no increase in SC indicating only minor activation of cells 
producing these cytokines in the environment of the SC. The temporal and relative changes in 
cytokine concentrations in the SC bag are due to known bioincompatibility mechanisms 
taking place 30,31.  
 
The chemical, electrical and three-dimensional properties of the column membrane or 
adsorbing beads is the basis for removal of LDL- cholesterol 32-34 and also affect 
biocompatibility properties and hence concentration change of cytokines. The LA15 and 
EC50 columns process plasma as compared to the DL75 column, which processes whole 
blood. Adding a second column, as in the plasma separation lipoprotein apheresis systems, 




there is a cross-talk between coagulation and inflammation, termed thromboinflammation, 
and manipulation of coagulation may influence the inflammatory response when foreign 
surfaces are exposed to blood 31,35. Unlike heparin, the thrombin inhibitor lepirudin, used as 
anticoagulation in this study, does not affect the complement system, an important biological 
factor for cytokine induction in bioincompatibility 36. This is of crucial importance when 
comparing our results with previous ex vivo as well as in vivo studies where heparin, citrate or 
ethylene diamine tetraacetic acid (EDTA) were used as anticoagulation. Our results show that 
the adsorption lipoprotein apheresis systems, DL75 and LA15, are more effective in reducing 
the presented biomarkers compared to the filtration lipoprotein apheresis system EC50.  
 
The temporal concentration change of eotaxin showed the difference between the whole blood 
and the plasma separation systems. In the LA15 and EC50 systems eotaxin was filtered into 
plasma only to a small extent per time unit, as the concentration in post plasmapheresis 
position PS1 fell immediately after the treatment started, indicating that the plasmaseparation 
column can be a barrier to removal of eotaxin. This might be explained by the chemical 
structure of eotaxin having a disordered N-terminus as compared to e.g. RANTES 37,38. No 
further removal was seen in the EC50 system. This indicates coating of the lipoprotein 
column membrane until saturation as the cause of the initial fall in concentration. Coating of 
foreign surfaces by plasma proteins has previously been described as the first step of the 
bioincompatibility process in contact between blood and foreign materials 39.  
 
Increase in concentration of VEGF was shown for all the apheresis systems tested compared 
to the SC indicating that tubing, columns and shear flow and shear stress had an impact on 
production of VEGF 40. Our results regarding VEGF are in contrast to former in vivo  studies 




to bind heparin 41 which is used for anticoagulation in clinical settings of lipoprotein 
apheresis, and this might explain the difference as heparin binding can enhance capture of 
VEGF in the lipoprotein apheresis columns in an in vivo setting.  
 
Platelets are activated and PDGF-BB released in the bioincompatibility process 42, and the 
immediate increase in PDGF-BB in the DL75 system at T15 is a characteristic first pass 
induction effect seen in this system. This could  probably be due to this column circulating 
whole blood and thus activating cytokine producing cells to a higher extent than the other 
lipoprotein apheresis columns. The direction of concentration change in PDGF-BB seen was 
the same as in an in vivo study, hence supporting the lipoprotein apheresis systems influence 
on PDGF-BB 23. 
  
The temporal concentration change of RANTES also demonstrated a difference between the 
whole blood and the plasma separation systems. The DL75 column, after a first pass 
induction, adsorbed RANTES leaving the final concentration below baseline. In the LA15 
system, the concentration at position BS2 was at the level of SC or slightly above at T240. It 
is tempting to assume that the plasma separation column participates in the induction of 
RANTES as the concentration in position PS1, after the plasma separation column, in the 
LA15 system increased during time. Hirata et al demonstrated that the plasma separation 
column activated the complement system but not cell components of the blood 43. A study on 
CD11b expression being complement factor 5 (C5) dependent, using the same plasma 
separation column, showed a clear C5 independent decrease in circulation platelets 44. These 
findings put together indicate that the plasma separation column does activate the platelets 
hence increasing the production of RANTES. An in vivo study found that the DL75 and LA15 




being contradictory with regard to the LA15 column 23. Stefanutti  et al. found, in an in vivo 
study using the DALI whole blood lipoprotein apheresis system, increase in RANTES, also 
contradictory to the findings in this study for the DL75 whole blood column, indicating a 
possible difference between whole blood lipoprotein apheresis systems with regard to 
concentration changes of RANTES 45.  
 
In the lipoprotein apheresis systems reduction of cytokine concentration could be seen either 
immediately or after a period of time. For IP-10 in the DL75 system a near complete removal 
from circulation was seen at T15, indicating an immediate adsorption. In the LA15 system 
there was a gradual reduction in IP-10 concentration during 240 minutes. The difference is 
probably due to the DL75 column adsorbing cytokines direct form whole blood, as compared 
to the LA15 system, which adsorbs cytokines from plasma. Our results indicate that IP-10 is 
not easily filtered through the pores of the plasmaseparation column, and this is mandatory for 
IP-10 to be available for adsorption in the lipoprotein apheresis column LA15 and EC50. The 
LA15 column was effective in adsorbing IP-10 as the concentration in post plasma separation 
position PS2 was low from T15. We have previously demonstrated an in vivo increase in IP-
10 with the same lipoprotein apheresis columns used in the present study 23. This may indicate 
that lipoprotein apheresis affects expression of IP-10 differently in an in vivo and an ex vivo 
setting. Recently Stefanutti et al. and others demonstrated an impact on the messenger RNA 
of IL-1α, IL-6, TNF in patients undergoing lipoprotein apheresis, indicating a possible 
regulatory effect on the expression of precursors in the chain of production of inflammatory 
mediators 46,47. This could contribute to explaining the observed differences between in effect 








The results presented in this ex vivo study demonstrate differences between the whole blood 
adsorption, dextran sulfate plasma adsorption and the double filtration plasmapheresis 
lipoprotein apheresis systems regarding their effects on cytokines, a fact that underlines the 
need to test every system independently, and not relying on results from similar or 
comparable systems. The results add to the current knowledge of effects of different 
lipoprotein apheresis systems on inflammatory mediators including temporal concentration 
changes, in ex vivo conditions. To answer the question whether differences in pattern changes 
of individual cytokines could play a role in therapeutic practice, further in vivo studies are 
needed, as this question is not answered in the present study. The results also underline the 
importance of studying biocompatibility processes not only in ex vivo but also in in vivo 
experiments close to the clinical setting in order to obtain a more complete understanding of 
the effects of contact between blood and the foreign material.  
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